Premium
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report
Author(s) -
Prignano F.,
Zanieri F.,
Milani S.,
Lotti T.
Publication year - 2009
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2009.01251.x
Subject(s) - efalizumab , medicine , psoriasis , etanercept , dermatology , disease , viral infection , viral load , plaque psoriasis , immunology , human immunodeficiency virus (hiv) , tumor necrosis factor alpha , virus
ABSTRACT Psoriasis vulgaris is a chronic dermatosis and is a widespread dematological disease. The most represented lesions are erythemato‐squamous plaques with a tendency to cover large body areas with a great impairment of normal activities and a poor quality of life. Very often psoriasis is associated to other illnesses and the dermatologist has to be aware that comorbidities have to be taken in account for a successfull treatment of the disease. We report a case of a patient affected by severe psoriasis and HCV infection. He underwent a first treatment with etenarcept with good clinical results and no change of his viral load. When etenarcept became ineffective, he received efalizumab, with a good control of his dermatological condition and a reduction of the viral load.